Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Seilern Investment Management increased its IDEXX Laboratories position by 20.7% in the second quarter, purchasing 16,729 shares. It now owns 97,560 shares worth approximately $51.4 million, representing 6.5% of its portfolio.
• Institutional investors and hedge funds own 87.84% of IDEXX’s outstanding stock, while several firms recently initiated or expanded their positions.
• IDEXX reported quarterly EPS of $4.27, beating estimates by $0.33, and revenue of $1.22 billion, up 9.7% year over year. Analysts maintain a “Moderate Buy” consensus, with an average price target of $756.

Seilern Investment Management Ltd raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 20.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,560 shares of the company's stock after buying an additional 16,729 shares during the quarter. IDEXX Laboratories comprises about 6.5% of Seilern Investment Management Ltd's portfolio, making the stock its 5th largest position. Seilern Investment Management Ltd owned about 0.12% of IDEXX Laboratories worth $51,359,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories during the third quarter valued at approximately $26,000. Elevation Wealth Partners LLC lifted its stake in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after purchasing an additional 32 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC lifted its stake in IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company's stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Finally, Wormser Freres Gestion boosted its holdings in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company's stock valued at $37,000 after purchasing an additional 47 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IDXX has been the topic of several recent analyst reports. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Weiss Ratings upgraded IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday, July 29th. UBS Group increased their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday. Finally, Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $756.00.

IDEXX Laboratories Trading Down 0.6%

NASDAQ IDXX opened at $586.67 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The company has a market cap of $46.22 billion, a price-to-earnings ratio of 41.26, a price-to-earnings-growth ratio of 3.18 and a beta of 1.54. The business's fifty day moving average is $559.73 and its 200 day moving average is $585.79.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.82 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source